Stage IV Small Cell Lung Cancer Causing Severe Cushing Syndrome

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Ectopic ACTH secretion with markedly elevated ACTH and cortisol

Metastatic Site: liver|bones

The cancer and hormone syndrome progressed after an initial response, and he died after cardiopulmonary arrest 1 year after diagnosis.

PubMed CentralRead more →

Small cell lung cancer presenting with spontaneous tumor lysis syndrome

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: liver

He developed rapidly worsening encephalopathy, gastrointestinal bleeding, cyanosis and mottling and died before planned chemotherapy could be started.

PubMed CentralRead more →

Autoimmune hemolytic anemia after 39 cycles of nivolumab for metastatic lung cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver, bone

While nivolumab remained on hold, his lung cancer was stable on imaging and clinically, and hemoglobin had recovered to 14.6 g/dL about 4 months after high-dose prednisone and rituximab began.

PubMed CentralRead more →

Stage IV ovarian cancer presenting as a persistent umbilical ulcer

Patient Info: Anonymized, Female, 40s | Stage IV

Metastatic Site: bilateral cardiophrenic lymph nodes

She recovered from extensive cytoreductive surgery without major abdominal or pulmonary complications and began adjuvant paclitaxel and carboplatin on postoperative day 25.

PubMed CentralRead more →

Stage IV Ovarian Cancer With 20 Years of Tumor-Free Survival

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1 negative, BRCA2 negative

Metastatic Site: peritoneum, liver, right adrenal gland

Regular follow-up found no recurrence or other tumor, and at 20 years of follow-up she remained tumor-free with good health and quality of life.

PubMed CentralRead more →

Recurrent Breast Cancer With Liver Metastases Treated Through Multiple Chemotherapy Lines

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: Initial tumor: ER positive, HER2 0. Liver metastasis: ER 100%

Metastatic Site: liver

After liver progression following 18 cycles of eribulin, she started weekly carboplatin and remained in active treatment.

PubMed CentralRead more →

Small cell lung cancer found after severe digestive and neurologic symptoms

Patient Info: Anonymized, Male, 50s

Biomarkers: ANNA-1 positive at 1:61, 440; neuronal acetylcholine receptor antibody 0.05 nmol/L

His speech and strength improved with treatment, and PET/CT 4 months after the initial assessment showed no recurrent or metastatic lung cancer.

PubMed CentralRead more →

Stage III Ovarian Cancer: Dianne's Patient Story

Patient Info: Dianne Simpson, female, 70+ | Stage III

Dianne completed treatment in April 2017 after chemotherapy, hysterectomy and a pembrolizumab clinical trial and was looking ahead to survivorship.

MD AndersonRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Treatment Intolerance and Progression

Patient Info: Anonymized, male

Biomarkers: ERBB2 A775_G776 insYVMA mutation

After poorly tolerated earlier regimens with stable disease, he developed symptomatic progression during 1 month of afatinib.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma Progressing Through Multiple Therapies

Patient Info: Anonymized, female

Biomarkers: ERBB2 mutation

The cancer progressed during afatinib, nivolumab and a later paclitaxel rechallenge.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Progression Across Multiple Regimens

Patient Info: Anonymized, male

Biomarkers: ERBB2 V777delinsVGSP mutation

After a brief period of stable disease on cisplatin plus docetaxel, the cancer progressed through erlotinib, gemcitabine and afatinib.

PubMed CentralRead more →

ERBB2-Mutated Stage III Lung Cancer With Liver Recurrence and Multiple Lines of Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion

Metastatic Site: liver

After 6 months of disease control on vinorelbine plus trastuzumab, the cancer progressed in all sites and she chose hospice care.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Adenocarcinoma Responding to HER2-Targeted Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion

Metastatic Site: bilateral lungs

Afatinib showed a response after 1 month, but insurance denial required a return to trastuzumab-based treatment.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Cancer With Extensive Bone Metastases

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion. A PIK3CA mutation was later detected at progression and considered a possible resistance mechanism.

Metastatic Site: bone

After progression on pemetrexed following several earlier treatment lines, she transitioned to hospice care.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Adenocarcinoma With Brain Metastases and Multiple Targeted Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ERBB2 exon 20 insertion, exact sequence not specified. ERBB2 copy-number gain was identified during progression on afatinib.

Metastatic Site: brain, adrenal gland, liver

The final documented afatinib plus bevacizumab rechallenge produced a mixed response followed by liver progression after 3 months.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Leptomeningeal Progression

Patient Info: Anonymized, male

Biomarkers: ERBB2 A775_G776 insYVMA mutation with amplification

The final treatment produced a mixed systemic response, but leptomeningeal disease developed.

PubMed CentralRead more →

Stage III Ovarian Cancer: Pam's Survivor Story

Patient Info: Pam Scarpino, female | Stage III

Pam had no evidence of disease in March 2010 after treatment for recurrence and remained in remission at the time of the story.

MD AndersonRead more →

Lung Cancer Immunotherapy Caused New Type 1 Diabetes

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No ALK, ROS1, KRAS or EGFR alteration was detected; CK7-positive; TTF-1-negative; PAX-negative; CK20-negative

Metastatic Site: Pleura

After 4 combination-treatment cycles, the right-lung nodules had decreased markedly and nearly resolved. He continued maintenance pembrolizumab every 3 weeks and remained on insulin with stable glucose control.

PubMed CentralRead more →

Lung Cancer Presenting With Tongue and Gastrointestinal Metastases

Patient Info: Anonymized, male, 40s

The cancer progressed after 2 cycles of carboplatin and pemetrexed, with worsening performance status, and chemotherapy was stopped.

PubMed CentralRead more →

Lung Adenocarcinoma Metastatic to the Breast With Inflammatory Breast-Like Symptoms

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR positive. Breast metastasis: TTF-1 positive

Metastatic Site: right breast

A PET scan after breast radiation showed no metabolically active cancer, but she died 2 months after the breast metastasis was diagnosed.

PubMed CentralRead more →

HER2-Positive Right Breast Cancer With Complete Response Before Bilateral Mastectomy

Patient Info: Anonymized, female, 50s

Biomarkers: ER negative, PR negative, HER2 positive

After neoadjuvant treatment, imaging showed complete resolution of the right-breast mass and mastectomy pathology found no residual right-breast tumor or malignant right sentinel node.

PubMed CentralRead more →

Ovarian Adenosquamous Cancer Treated With Surgery and Chemotherapy

Patient Info: Anonymized, female, 50s | Stage I

Five and a half years after chemotherapy, she remained free of recurrence.

PubMed CentralRead more →

Ovarian Cancer With Severe Dermatomyositis During Treatment

Patient Info: Anonymized, female, 60s | Stage III

Biomarkers: BRCA1 mutation

She continued paclitaxel and carboplatin while being treated for severe dermatomyositis and later described herself as finally on the mend.

PubMed CentralRead more →

Stage I Ovarian Squamous Cell Cancer Found in a Long-Standing Dermoid Cyst

Patient Info: Anonymized, female, 40s | Stage I

At 22 months after treatment, she had no clinically identifiable recurrence.

PubMed CentralRead more →